Ask AI

Novel C5 Inhibitors in Generalized Myasthenia Gravis: Using Mechanism to Inform Management

Research shows that approximately 62% of patients with myasthenia gravis receiving chronic treatment continued to experience moderate to severe symptoms, underscoring the need for more individualized disease management. Through these slides, explore evidence for approved and emerging C5 inhibitors, the role of FcRn-directed approaches, and practical considerations such as safety, treatment burden, response assessment, switching, access, and patient preferences.

Myasthenia Gravis Management

Activity Information

Released: August 31, 2026